Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)

This publication has 25 references indexed in Scilit:

• Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
  European Heart Journal, 2006
• Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y₁₂Receptor Antagonist Activity
  Seminars in Thrombosis and Hemostasis, 2005
• Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention
  Circulation, 2005
• Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets
  Circulation, 2005
• Variability in platelet responsiveness to clopidogrel among 544 individuals
  JACC, 2005
• Clopidogrel Resistance
  Circulation, 2004
• Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction
  Circulation, 2004
• Clopidogrel for Coronary Stenting
  Circulation, 2003
• The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease
  European Heart Journal, 2000
• The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
  British Journal of Pharmacology, 2000